Cargando…

Impact of Molecular Drug Susceptibility Testing on the Time to Multidrug-resistant Tuberculosis Treatment Initiation

BACKGROUND: The purpose of this study was to evaluate the current status and trends in the coverage of molecular drug susceptibility testing (mDST), and the impact of mDST on the time to multidrug-resistant tuberculosis (MDR-TB) treatment initiation in Korea. METHODS: We included confirmed rifampin-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jeon, Doosoo, Kang, Hyungseok, Kwon, Yong-Soo, Yim, Jae-Joon, Shim, Tae Sun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Academy of Medical Sciences 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476798/ https://www.ncbi.nlm.nih.gov/pubmed/32893517 http://dx.doi.org/10.3346/jkms.2020.35.e284

Ejemplares similares

The Interval Between Initiation of Anti-tuberculosis Treatment in Patients with Culture-positive Pulmonary Tuberculosis and Receipt of Drug-susceptibility Test Results
por: Joh, Joon-Sung, et al.
Publicado: (2007)

Medical Management of Drug-Resistant Tuberculosis
por: Jeon, Doosoo
Publicado: (2015)

Additional Drug Resistance Patterns among Multidrug-Resistant Tuberculosis Patients in Korea: Implications for Regimen Design
por: Mok, Jeong Ha, et al.
Publicado: (2017)

Additional Drug Resistance in Patients with Multidrug-resistant Tuberculosis in Korea: a Multicenter Study from 2010 to 2019
por: Lee, Taehoon, et al.
Publicado: (2021)

Treatment of Drug Susceptible Pulmonary Tuberculosis
por: Shin, Hong-Joon, et al.
Publicado: (2015)

Fluoroquinolone resistance in multidrug-resistant tuberculosis patients
por: Lee, Hyun-Woo, et al.
Publicado: (2019)

WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update: Applicability in South Korea
por: Jeon, Doosoo
Publicado: (2017)

Impact of Anti-Tuberculosis Drug Use on Treatment Outcomes in Patients with Pulmonary Fluoroquinolone-Resistant Multidrug-Resistant Tuberculosis: A Nationwide Retrospective Cohort Study with Propensity Score Matching
por: Choi, Hongjo, et al.
Publicado: (2023)

Multidrug-Resistant Musculoskeletal Tuberculosis: An Aggressive Clinical, Radiological and Molecular Confirmation With Genotypic Drug Susceptibility Testing Approach
por: Sethi, Vikram, et al.
Publicado: (2022)

Retreatment after loss to follow-up reduces mortality in patients with multidrug/rifampicin-resistant tuberculosis
por: Choi, Hongjo, et al.
Publicado: (2023)

Impact of universal drug susceptibility testing and effective management of multidrug-resistant tuberculosis in Taiwan
por: Lee, Pin-Hui, et al.
Publicado: (2019)

A comparison of phenotypic and WGS drug susceptibility testing in Mycobacterium tuberculosis isolates from the Republic of Korea
por: Lee, Seung Heon, et al.
Publicado: (2023)

Different macrophage polarization between drug-susceptible and multidrug-resistant pulmonary tuberculosis
por: Cho, Hyun Jin, et al.
Publicado: (2020)

Treatment Outcome and Mortality among Patients with Multidrug-resistant Tuberculosis in Tuberculosis Hospitals of the Public Sector
por: Jeon, Doo Soo, et al.
Publicado: (2011)

Latent tuberculosis infection: recent progress and challenges in South Korea
por: Jeon, Doosoo
Publicado: (2020)

Protocol of a Nationwide Observational Study among Patients with Nontuberculous Mycobacterium Pulmonary Disease in South Korea (NTM-KOREA)
por: Kwak, Nakwon, et al.
Publicado: (2020)

Trend of multidrug and fluoroquinolone resistance in Mycobacterium tuberculosis isolates from 2010 to 2014 in Korea: a multicenter study
por: Kim, Hyeonseok, et al.
Publicado: (2019)

Cost-Effectiveness Comparison of Genechip and Conventional Drug Susceptibility Test for Detecting Multidrug-Resistant Tuberculosis in China
por: Pang, Yu, et al.
Publicado: (2013)

Application of quantitative second-line drug susceptibility testing at a multidrug-resistant tuberculosis hospital in Tanzania
por: Mpagama, Stellah G, et al.
Publicado: (2013)

Individualized Treatment of Multidrug-resistant Tuberculosis Using Whole-Genome Sequencing and Expanded Drug-Susceptibility Testing
por: Dookie, Navisha, et al.
Publicado: (2020)

Treatment shortening of drug-sensitive pulmonary tuberculosis using high-dose rifampicin for 3 months after culture conversion (Hi-DoRi-3): a study protocol for an open-label randomized clinical trial
por: Kwak, Nakwon, et al.
Publicado: (2022)

Drug-Susceptible and Multidrug-Resistant Mycobacterium tuberculosis in a Single Patient
por: Baffoe-Bonnie, Anthony, et al.
Publicado: (2019)

Resistance to Second-Line Antituberculosis Drugs and Delay in Drug Susceptibility Testing among Multidrug-Resistant Tuberculosis Patients in Shanghai
por: Chen, Yong, et al.
Publicado: (2016)

Nationwide Treatment Outcomes of Patients With Multidrug/Rifampin-Resistant Tuberculosis in Korea, 2011–2017: A Retrospective Cohort Study (Korean TB-POST)
por: Choi, Hongjo, et al.
Publicado: (2023)

Medical Treatment of Pulmonary Multidrug-Resistant Tuberculosis
por: Shim, Tae Sun, et al.
Publicado: (2013)

Molecular drug susceptibility testing and strain typing of tuberculosis by DNA hybridization
por: Wood, Hillary N., et al.
Publicado: (2019)

Co-infection with Drug-Susceptible and Reactivated Latent Multidrug-Resistant Mycobacterium tuberculosis
por: Pérez-Lago, Laura, et al.
Publicado: (2015)

Radiological Findings of Extensively Drug-Resistant Pulmonary Tuberculosis in Non-AIDS Adults: Comparisons with Findings of Multidrug-Resistant and Drug-Sensitive Tuberculosis
por: Cha, Jihoon, et al.
Publicado: (2009)

Genetic Diversity and Drug Susceptibility Profiles of Multidrug-Resistant Tuberculosis Strains in Southeast China
por: Lin, Shufang, et al.
Publicado: (2021)

Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial
por: Lee, Myungsun, et al.
Publicado: (2019)

Evaluation of MGIT 960 System for the Second-Line Drugs Susceptibility Testing of Mycobacterium tuberculosis
por: Kim, Hyejin, et al.
Publicado: (2013)

Multidrug-resistant Tuberculosis Lymphadenitis as the Initial Presentation of Secondary Multidrug-resistant Tuberculosis: A Case Report
por: Ogundipe, Temitayo, et al.
Publicado: (2018)

Evaluation of four colourimetric susceptibility tests for the rapid detection of multidrug-resistant Mycobacterium tuberculosis isolates
por: Coban, Ahmet Yilmaz, et al.
Publicado: (2015)

Evaluation of microscopic observation drug susceptibility assay for diagnosis of multidrug-resistant Tuberculosis in Viet Nam
por: Minh Ha, Dang Thi, et al.
Publicado: (2012)

Quantitative Drug-Susceptibility in Patients Treated for Multidrug-Resistant Tuberculosis in Bangladesh: Implications for Regimen Choice
por: Heysell, Scott K., et al.
Publicado: (2015)

Transmission of Multidrug-Resistant and Drug-Susceptible Tuberculosis within Households: A Prospective Cohort Study
por: Grandjean, Louis, et al.
Publicado: (2015)

Diagnostic Accuracy of GeneXpert MTB/RIF Assay in Comparison to Conventional Drug Susceptibility Testing Method for the Diagnosis of Multidrug-Resistant Tuberculosis
por: Pandey, Pratikshya, et al.
Publicado: (2017)

Concomitant Multidrug-resistant Pulmonary Tuberculosis and Susceptible Tuberculous Meningitis
por: Bernard, Christine, et al.
Publicado: (2014)

Status of Universal Drug Susceptibility Testing in Pulmonary Tuberculosis Patients Initiated on Treatment in an Urban Setting, South India
por: Velayutham, Banurekha, et al.
Publicado: (2023)

Retrospective Comparison of Levofloxacin and Moxifloxacin on Multidrug-Resistant Tuberculosis Treatment Outcomes
por: Lee, Jinwoo, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_fg80oo9b4jg509hsbcmmls50if